02 June 2003 00:00 [Source: ICB]AstraZeneca has opened its £90m (E125m/$147m) bulk drug manufacturing facility at its Avlon works, near Bristol, UK. The investment provides for the worldwide supply of rosuvastatin, the active ingredient for Crestor, a once-daily treatment for dyslipidaemia, a key risk factor in the development of coronary disease.
The facilities house processes for synthesis, purification, drying and milling. The resources comprise two major new plants, the first of which has been operational for some time, and associated infrastructure. Quality assurance and warehousing forms part of the site. AstraZeneca's Avlon works employs over 400 people in manufacturing.
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.
Sample issue >>
My Account/Renew >>
Register for online access >>
|ICIS Top 100 Chemical Companies|
|Download the listing here >>|
Asian Chemical Connections